Table 4 Outcome analysis distributed by clinical-pathogenetic aspects
Total(n = 94) | EOMG(n = 45) | LOMG(n = 28) | TAMG(n = 21) | p-value | |
|---|---|---|---|---|---|
Follow up (m) | |||||
46 [12;151] | 44 [12;151] | 45 [14;74] | 49 [18;107] | 0.699 | |
MG-ADL postOP | |||||
2 [0;16] | 3 [0;12] | 0 [0;8] | 2 [0;16] | 0.298 | |
MG-QoL | |||||
3,5 [0;28] | 5 [0;27] | 2 [0;17] | 7 [0;28] | 0.242 | |
qMG | |||||
1 [0;18] | 1 [0;17] | 0 [0;15] | 2 [0;18] | 0.776 | |
MG-Composite | |||||
1 [0;27] | 1.5 [0;21] | 0 [0;8] | 2 [0;27] | 0.407 | |
AchR (nmol/l) | |||||
4,5 [0;674] | 3 [0;674] | 4,5 [0,12;85] | 5.4 [1,8;273] | 0.42 | |
PIS | 0.031 | ||||
CSR | 10.6 | 18.8 | 4.8 | 0 | |
MM0 | 9.1 | 15.6 | 4.8 | 0 | |
MM1 | 12.1 | 6.3 | 19.0 | 15.4 | |
MM2 | 4.5 | 9.4 | 0 | 0 | |
MM3 | 63.6 | 50 | 71.4 | 84.6 | |
0.25 | |||||
Improved | 56.9 | 51.6 | 61.9 | 61.5 | |
Unchanged | 29.2 | 38.7 | 19 | 23.1 | |
Worse | 13.8 | 9.7 | 19 | 15.4 |